A 58-year-old nurse from Scotland has died after taking two doses of weight-loss drug tirzepatide, also known as Mounjaro or ...

Eli Lilly is studying two weight loss candidates in phase 3 trials ... A small player like Viking may also win by attracting ...

We recently published a list of 10 Best Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

Despite the above, there are still a couple of silver linings that provide more than enough reason to be bullish about this stock.

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Eli Lilly has said it is prepared to invest £279 ... the dual GIP/GLP-1 receptor agonist in the company's Mounjaro drug for type 2 diabetes and obesity. The SURMOUNT-REAL UK study will be carried ...

Shares of Nvidia surged to a record high on Thursday, marking a historic milestone as the chipmaker became the first company ...

The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...

Eli Lilly and Incyte's Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair loss that affects more than 700,000 ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

CENTRAL GOVERNMENT FUNDS: Social welfare would account for the largest portion of the NT$3.33 trillion budget, followed by spending on education, tech and culture ...